STENOCARE raised capital via an IPO on Spotlight Stock Market in Q3/Q4 2018 to start the project of establishing their own cultivation facility in Denmark. This project has several phases and, apart from the not yet received plant seedling export certificate, this is progressing as expected. STENOCARE has secured sourcing of live plant seedlings from their strategic partner, CannTrust Inc., that has many years of experience and development with cannabis plants. These unique plants will help STENOCARE produce medical cannabis products in high quality and with uniform strengths and content in a controlled indoor environment. STENOCARE has worked with The Danish Agricultural Agency and The Danish Medicines Agency for the import of plant seedlings for their Danish cultivation facility. These Agencies have issued import certificates that enable STENOCARE to import the live plant materials from their strategic partner (CannTrust Inc.) in Canada. The company is expecting that the Canadian Agencies will very soon complete the corresponding export certificates for the seedlings. STENOCARE is ready to receive the live plant seedlings from Canada and are eager to commence the 1ststage cultivation at their facility in Denmark. STENOCARE will submit a separate press-release upon receipt of the awaited export certificate.